Bioinformatics Research on Inter-racial Dijerence in Drug Metabolism I. Analysis on Frequencies of Mutant Alleles and Poor Metabolizers on CYP2D6 and CYP2C19

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 1, 2003, Pages 48-70

  Shimizu, Takako ^a   Katada, Jun ^a   Hashimoto, Munehiro ^a   Matsui, Hitoshi ^a   Aida, Yoshitaka ^a   Ohashi, Akira ^a   Ozawa, Naoki ^a   Ochiai, Hirohide ^b   Fredrik, Asell ^b   Shimizu, Hiroshi ^b   Saitoh, Ryuta ^b   Hama, Yoshimasa ^b   Taki, Katsuhiko ^c   Kaminuma, Tsuguchika ^d   Yamamoto, Michiko ^d  

^a Pharmacia   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c Nihon Visual Science   (Japan)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

drug metabolism; genetic polymorphism; inter racial dijerence; poor metabolizer

Indexed keywords

EID: 85006639536     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.48     Document Type: Article

References (224)

1. Küpfer, A. and Preisig, R.: Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol., 26: 753-759 (1984).
2. Mahgoub, A., Idle, J. R., Dring, L. G. and Lancaster, R.: Polymorphic hydroxylation of debrisoquine in man. Lancet, 17: 584-586 (1977).
3. Eichelbaum, M., Spannbrucker, N., Steincke, B. and Dengler, H. J.: Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur. J. Clin. Pharmacol., 16: 183-187 (1979).
4. Bertilsson, L., Åberg-Wistedt, A., Gustafsson, L. L. and Nordin, C.: Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther. Drug Monit., 7: 478-480 (1985).
5. Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjoqvist, F., Spina, E. and Brockmoller, J.: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta. Psychiatr. Scand., 104: 173-192 (2001).
6. Fujieda, M., Yamazaki, H. and Kamataki, T.: Genetic polymorphism of drug metabolizing enzymes. Jpn. J. Cancer Chemother., 29(5): 663-668 (2002).
7. Saruwatari, T., Nakagawa K. and Ishizaki, T.: Genetic polymorphisms in drug-metabolizing enzymes. Nippon Rinsho, 60: 58-63 (2002).
8. Poolsup, N., Po, A. L. W. and Knight, T. L.: Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther., 25: 197-220 (2000).
9. Ingelman-sundberg, M., Oscarson, M. and McLellan, R. A.: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci., 20: 342-349 (1999).
10. Xie, H.-G., Kim, R. B., Wood, A. J. J. and Stein, C. M.: Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol., 41: 815-850 (2001).
11. Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A. and Gonzalez, F. J.: The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet., 45: 889-904 (1989).
12. Nishida, Y., Fukuda, T., Yamamoto, I. and Azuma, J.: CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics, 10: 567-570 (2000).
13. Dahl, M.-L., Yue, Q.-Y., Roh, H.-K., Johasson, I., Sawe, J., Sjoqvist, F. and Bertilsson, J.: Genetic analysis of the CYP2D6 locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics, 5: 159-164 (1995).
14. Tateishi, T., Chida, M., Ariyoshi, N., Mizorogi, Y., Kamataki, T. and Kobayashi, S.: Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther., 65: 570-575 (1999).
15. Setou, K., Ieiri, I., Fujii, K., Higuchi, S., Kimura, M., Urae, A., Irie, S. and Ohtsubo, K.: Jpn. J. Clin. Pharmacol. Ther., 30: 79-80 (1999).
16. Johansson, I., Oscarson, M., Yue, Q.-Y., Bertilsson, L., Sjöqvist, F. and Ingelman-Sundberg, M.: Genetic analysis of the Chinese cytochrome P4502D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol., 46: 452-459 (1994).
17. Kubota, T., Yamaura, Y., Ohkawa, N., Hara, H. and Chiba, K.: Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol., 50: 31-34 (2000).
18. Teh, L. K., Ismail, R., Yusoff, R., Hussein, A., Isa, M. N. and Rahman, A. R. A.: Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J. Clin. Pharm. Ther., 26: 205-211 (2001).
19. Droll, K., Brouce-Mensah, K., Otton, S. V., Gaedigk, A., Sellers, E. M. and Tyndale, R. F.: Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics, 8: 325-333 (1998).
20. Tao, E., Liu, Z., Chen, B., Pan, X. and Shao, M.: Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease. Chin. J. Med. Genet., 15: 281-283 (1998).
21. Pang, C. P., Zhang, J., Woo, J., Chan, D., Law, L. K., Tong, S. F., Kwok, T. and Kay, R.: Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease. Mov. Disord., 13: 529-532 (1998).
22. Ryu, S.-W., Kim, Y.-J. and Kim, E.: Mutation analysis of CYP2D6 locus in the Korean population: identification of rare poor metabolizer alleles at the nucleotide level. Mol. Cells, 8: 758-763 (1998).
23. Ismail, R. and Teh, L. K.: Genetic polymorphism of CYP2D6: Malaysian indians have the highest frequency for CYP2D6*4 in Asia. Eur. J. Clin. Pharmacol., 57: 617-618 (2001).
24. Weerasuriya, K., Jayakody, R. L., Smith, C. A. D., Wolf, C. R., Tucker, G. T. and Lennard, M. S. Debrisoquine and mephenytoin oxidation in Sinhalese a population study. Br. J. Clin. Pharmacol., 38 466-470 (1994).
25. Chen, X., Xia, Y., Gresham, L. S., Molgaard, C. A., Thomas, R. G., Galasko, D., Wiederholt, W. C. and Saitoh, T.: ApoE and CYP2D6 polymorphism with and without parkinsonism-dementia complex in the people of Chamorro, Guam. Neurology, 47: 779-784 (1996).
26. Buch, S., Kotekar, A., Kawle, D. and Bhisey, R.: Polymorphisms at CYP and GST gene loci. Eur. J. Clin. Pharmacol., 57: 553-555 (2001).
27. Wang, S.-L., Huang, J., Lai, M.-D., Liu, B.-H. and Lai, M.-L.: Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther., 53: 410-418 (1993).
28. Lee, E. J. D. and Jeyaseelan, K.: Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br. J. Clin. Pharmacol., 37: 605-607 (1994).
29. Roh, H. K., Dahl, M. L., Johansson, I., Ingelman-Sundberg, M., Cha, Y. N. and Bertilsson, L.: Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics, 6: 441-447 (1996).
30. Cai, W., Chen, B., Tao, X., Ling, S. and Zhang, Y.: Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese. Chin. J. Med. Genet., 17: 181-184 (2000).
31. Wang, S. L., Lai, M.-D. and Huang, J.-D.: G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab. Dispos., 27: 385-388 (1999).
32. Yokoi, T., Kosaka, Y., Chiba, M., Nakamura, H., Ishizaki, T., Kinoshita, M., Sato, K., Gonzalez, F. J. and Kamataki, T.: A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics, 6: 395-401 (1996).
33. Kubota, T., Hibi, N. and Chiba, K.: Linkage of mutant allele of CYP2C18 and CYP2C19 in a Japanese population. Biochem. Pharmacol., 55: 2039-2042 (1998).
34. Tsuneoka, Y., Fukushima, K., Matsuo, Y., Ichikawa, Y. and Watanabe, Y.: Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci., 59: 1711-1715 (1996).
35. Roh, H.-K., Dahl, M.-L., Tybring, G., Yamada, H., Cha, Y.-N. and Bertilsson, L.: CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 6: 547-551 (1996).
36. Itoh, K., Inoue, K., Yanagawa, S., Kyoya, H. and Suzuki, T.: A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Biol. Pharm. Bull., 22: 77-79 (1999).
37. Takakubo, F., Kuwano, A. and Kondo, I.: Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics, 6: 265-267 (1996).
38. Kimura, M., Ieiri, I., Mamiya, K., Urae, A. and Higuchi, S.: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit., 20: 243-247 (1998).
39. Yao, T. W., Zeng, S., Wang, T. W. and Chen, W. Q.: Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. Biomed. Chromatogr., 15: 9-13 (2001).
40. Ko, J.-W., Macpherson, A. S., Jang, I.-J., Shin, S.-G. and Flochart, D. A.: The incidence of genetic polymorphisms of CYP 2C in a Korean population. Clin. Pharmacol. Ther., 61: 226 (1997).
41. Nowak, M. P., Sellers, E. M. and Tyndale, R. F.: Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin. Pharmacol. Ther., 64: 378-383 (1998).
42. Xiao, Z.-S., Goldstein, J. A., Xie, H.-G., Blaidell, J., Wang, W., Jiang, C.-H., Yan, F.-X., He, N., Huang, S.-L., Xu, Z.-H. and Zhou, H.-H.: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther., 281: 604-609 (1997).
43. Goldstein, J. A., Ishizaki, T., Chiba, K., de Morais, S. M. F., Bell, D., Krahn, P. M. and Evans, A. P.: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian an American black populations. Pharmacogenetics, 7: 59-64 (1997).
44. Tanigawara, Y., Kita, T., Hirono, M., Sakaeda, T., Komada, F. and Okumura, K.: Identification of N-acetyltransferase 2 and CYP2C19 genotypes for hair, buccal cell swabs, or fingernails compared with blood. Ther. Drug Monit., 23: 341-346 (2001).
45. Kubota, T., Chiba, K. and Ishizaki, T.: Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther., 60: 661-666 (1996).
46. Griese, E.-U., Zanger, U.M., Brudermanns, U., Gaedigk, A., Mikus, G., Mdrike, K., Stiiven, T. and Eichelbaum, M.: Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics, 8: 15-26 (1998).
47. Bandmann, O., Vaughan, J., Holmans, P., Marsden, C. D. and Wood, N. W.: Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet, 350: 1136-1139 (1997).
48. Agilndez, J. A. G., Olivera, M., Ladero, J. M., Rodriguez-Lescure, A., Ledesma, M. C., Diaz-Rubio, M., Meyer, U. A. and Benitez, J.: Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizer. Pharmacogenetics, 6: 501-512 (1996).
49. Wan, Y.-J.Y., Poland, R. E., Han, G., Konishi, T., Zheng, Y.-P., Berman, N. and Lin, K.-M.: Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-American in Southern California. Pharmacogenetics, 11: 489-499 (2001).
50. Gaedigk, A., Gotschall, R. R., Forbes, N. S., Simon, S. D., Kearns, G. L. and Leeder J. S.: Optimization of cytochrome P4502D6 (CYP2Dphenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics, 9: 669-682 (1999).
51. Ladona, M. G., Izquierdo-Martinez, M., Posada de la Paz, M., De la Torre, R., Ampurdanes, C., Segura, J. and Sanz, E. J.: Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome. Environ. Health Perspect., 109: 369-375 (2001).
52. Leathart, J. B. J., London, S. J., Steward, A., Adams, J. D., Idle, J. R. and Daly, A. K.: CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics, 8: 529-541 (1998).
53. Agilndez, J. A. G., Gallardo, L., Ledesma, M. C., Lozano, L., Rodriguez-Lescure, A., Pontes, J. C., Iglesias-Moreno, M. C., Poch, J., Ladero, J. M. and Benitez, J.: Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology, 61: 59-63 (2001).
54. Hamelin, B. A., Dorson, P. G., Pabos, D., Still, D., Bouchard, R.-H., Pourcher, E., Rail, J., Turgeon, J. and Crismon, M. L.: CYP2D6 mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy, 19: 1057-1063 (1999).
55. Tyndale, R. F., Droll, K. P. and Sellers, E. M.: Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics, 7: 375-379 (1997).
56. Marandi, T., Dahl, M. L., Rägo, L., Kiivet, R. and Sjoqvist, F.: Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. Eur. J. Clin. Pharmacol., 53: 257-260 (1997).
57. Hersberger, M., Marti-Jaun, J., Rentsch, K. and Hänseler, E.: Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin. Chem., 46: 1072-1077 (2000).
58. Akhmedova, S. N., Pushnova, E. A., Anisimov, S., Bogdanova, L. A., Bova, K. L. and Schwarts, E. I.: Brief Communication CYP2D6 genotyping in a Russian population using a novel approach for identification of the CYP2D6A mutation. Biochem. Mol. Med., 58: 234-236 (1996).
59. Graf, T., Broly, F., Hoffmann, F., Probst, M., Meyer, U. A. and Howald, H.: Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur. J. Clin. Pharmacol., 43: 399-403 (1992).
60. Smith, C. A. D., Gough, A. C., Leigh, P. N., Summers, B. A., Harding, A. E., Maranganore, D. M., Sturman, S. G., Schapira, A. H. V., Williams, A. C., Spurr, N. K. and Wolf, D. R.: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, 339: 1375-1377 (1992).
61. Terfe, T., Daly, A. K., Armstrong, M., Leathart, J. B. S., Idle, J. R., Brøgger, A. and Borresen, A.-L.: Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics, 4: 47-57 (1994).
62. Mattsson, P., Bjelfman, C., Lundberg, P. O. and Rane, A.: Cytochrome P450 2D6 and glutathione S-transferase M1genotypes and migraine. Eur. J. Clin. Invest., 30: 367-371 (2000).
63. Yamada, H., Dahl, M.-L., Lannfelt, L., Viitanen, M., Winblad, B. and Sjöqvist, F.: CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur. J. Clin. Pharmacol., 54: 479-481 (1998).
64. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A., Pelkonen, O. and Vainio H.: PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics, 3: 19-27 (1993).
65. Marsh, J. C., Chowdry, J., Parry-Jones, N., Ellis, S. W., Muir, K. R., Gordon-Smith, E. C. and Tucker, G. T.: Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia. Br. J. Haematol., 104: 266-270 (1999).
66. Roddam, P. L., Rollinson, S., Kane, E., Roman, E., Moorman, A., Cartwright, R. and Morgan, G. J.: Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics, 10: 605-615 (2000).
67. Labuda, D., Krajinovic, M., Richer, C., Skoll, A., Sinnett, H., Yotavo, V. and Sinnett, D.: Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal. Biochem., 275: 84-92 (1999).
68. Pirmohamed, M., Wild, M. J., Kitteringham, N. R., O'Brien, K., Buchan, I. E., Back, D. J. and Park, B. K.: Letter to the Editor Lack of association between schizophrenia and the CYP2D6 gene polymorphisms. Am. J. Med. Genet. (Neuropsychiatric Genetics), 67: 236-237 (1996).
69. Beyler, C., Armstrong, M., Bird, H. A., Idle, J. R. and Daly, A. K.: Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann. Rheum. Dis., 55: 66-68 (1996).
70. Dawson, E., Powell, J. F., Nöthen, M. M., Crocq, M.-A., Lanczik, M., Körner, J., Rietschel, M., van Os, J., Wright, P. and Gill, M.: An association study of debrisoquine hydroxylase (CYP2Dpolymorphisms in schizophrenia. Psychiatr. Genet., 4: 215-218 (1994).
71. Daniels, J., Williams, J., Asherson, P., McGuffin, P. and Owen, M.: No association between schizopherenia and polymorphisms within the genes for debrisoquine 4-hydoxylase (CYP2Dand the dopamine transporter (DAT). Am. J. Med. Genet. (Neuropsychiatric Genetics), 60: 85-87 (1995).
72. Bernal, M. L., Sinues, B., Johansson, I., McLellan, R. A., Wennerholm, A., Dahl, M.-L., Ingelman-Sundberg, M. and Bertilsson, L.: Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics, 9: 657-660 (1999).
73. Bon, M. A. M., Steur, E.N.H.J., de Vos, R. A. I. and Vermes, I.: Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism. Neurosci. Lett., 266: 149-151 (1999).
74. Martin, D. E., Tran, J. Q., Flockhart, D. A. and Jorkasky, D. K.: Analysis of the CYP2D6 and 2C19 genotype in large African-American (AA) and Caucasian (C) populations. Clin. Pharmacol. Ther., 63: 206 (1998).
75. Zimmermann, T., Schlenk, R., Pfaff, G., Lach, P. and Wildfeuer, A.: Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers. Drug Res., 45: 41-43 (1995).
76. Longuemaux, S., Deloménie, C., Gallou, C., Méjean, A., Vincent-Viry, M., Bouvier, R., Droz, D., Krishnamoorthy, R., Galteau, M.-M., Junien, C., Beroud, C. and Dupret, J.-M.: Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res., 59: 2903-2908 (1999).
77. Muiras, M.-L., Verasdonck, P., Cottet, F. and Schachter, F.: Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci. Hum. Genet., 102: 526-532 (1998).
78. Lucotte, G., Turpin, J.-C., Gérard, N., Panserat, S. and Krishnamoorthy, R.: Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families. Am. J. Med. Genet. (Neuropsychiatric Genetics), 67: 361-365 (1996).
79. Bordet, R., Broly, F., Destée, A., Libersa, C. and Lafitte, J. J.: Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease. Clin. Neurophar-macol., 19: 213-221 (1996).
80. Harhangi, B. S., Oostra, B. A., Heutink, P., van Duijn, C. M., Hofman, A. and Breteker, M. M. B.: CYP2D6 polymorphism in Parkinson's disease: The Rotterdam study. Mov. Disord., 16: 290-293 (2001).
81. Madsen, H., Nielsen, K. K. and Brøsen, K.: Imipra-mine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms a population study. Br. J. Clin. Pharmacol., 39: 433-439 (1995).
82. Marandi, T., Dahl, M. L., Kiivet, R. A., Rägo, L. and Sj÷qvist, F.: Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. Pharmacol. Toxicol., 78: 303-307 (1996).
83. Štefanović, M., Topić, E., Ivaniěvić, A.-M., Relji, M. and Korĭć, M.: Genotyping of CYP2D6 in Parkinson's disease. Clin. Chem. Lab. Med., 38: 929-934 (2000).
84. Dolžan, V., Rudolf, Z. and Breskvar, K.: Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis, 16: 2675-2678 (1995).
85. Gawrońska-Szklaz, B., Wójcicki, M., Kuprianowicz, A., Kedzierska, K., Kedzierski, M., Górnik, W. and Pawlik, A.: CYP2D6 and GSTM1 genotypes in a Polish population. Eur. J. Clin. Pharmacol., 55: 389-392 (1999).
86. Scarlett, L. A., Madani, S., Shen, D. D. and Ho, R. J. Y.: Development and characterization of a rapid and comprehensive genotyping assay to detect the most common variants in cytochrome P450 2D6. Pharm. Res., 17: 242-246 (2000).
87. Sandy, M. S., Armstrong, M., Tanner, C. M., Daly, A. K., Monte, D. A., Langston, J. W. and Idle, J. R.: CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology, 47: 225-230 (1996).
88. McCann, S. J., Pond, S. M., James, S. M. and Le Couteur, D. G.: The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Sci., 153: 50-53 (1997).
89. Lyakhovich, V. V., Mitrofanov, D. V., Gutkina, N. I., Duzhak, T. G., Posukh, O. L. and Osipova, L. P.: Genetic polymorphism of CYP1A1 and CYP2D6 in the Tundra Nentsi population of Siberia. Int. J. Circumpo-lar Health, 57: 725-729 (1998).
90. Butler, W. J., Ryan, P. and Roberts-Thomson, I. C.: Metabolic genotypes and risk for colorectal cancer. J. Gastroenterol. Hepatol., 16: 631-635 (2001).
91. Gasser, T., Müller-Myhsok, B., Supala, A., Zimmer,E., Wieditz, G., Wszolek, Z. K., Vieregge, P. Bonafati, V. and Oertel, W. H.: The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 61: 518-520 (1996).
92. Smith, C. A. D., Moss, J. E., Gough, A. C., Spurr, N. K. and Wolf, C. R.: Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ. Health Perspect., 98: 107-112 (1992).
93. Lemos, M. C., Carbrita, F. J., Silva, H. A., Vinvan, M., Placido, F. and Regateiro, F. J.: Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis, 20: 1225-1229 (1999).
94. González, M. V., Alvarez, V., Pello, M. F., Menendez, M. J., Suarez, C. and Coto, E.: Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J. Clin. Pathol., 51: 294-298 (1998).
95. Rossi, A. M., Guarnieri, C., Rovesti, S., Gobba, F., Ghittori, S., Vivoli, G. and Barale, R.: Genetic polymorphisms influence variability in benzene metabolism in humans. Pharmacogenetics, 9: 445-451 (1999).
96. Kurth, M. C., Kurth, J. H., Hubble, J. P., Sliger, L., Eggers, B., Lieberman, A. N. and Koller, W. C.: Genetic evidence of differences in Parkinson's disease susceptibility by CYP2D6 and MAOB genotypes. Am. J. Hum. Genet., 57SS: 1964 (1995).
97. Daly, A. K., Leathart, J. B. S., London, S. J. and Idle, J. R.: An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum. Genet., 95: 337-341 (1995).
98. Saxena, R., Shaw, G. L., Relling, M. V., Frame, J. N., Moir, D. T., Evans, W. E. and Caporaso, B. W.: Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet., 3: 923-926 (1994).
99. Broly, F., Marez, D., Lo Guidice, J.-M., Sabbagh, N., Legrand, M., Boone, P. and Meyer, U. A.: A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum. Genet., 96: 601-603 (1995).
100. Marez, D., Sabbagh, N., Legrand, M., Lo-Guidice, P. and Broly, F.: A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics, 5: 305-311 (1995).
101. Marez, D., Legrand, M., Sabbagh, N., Lo-Guidice, J. M., Boone, P. and Broly, F.: An additional allelic variant of CYP2D6 gene causing impaired metabolism of sparteine. Hum. Genet., 97: 668-670 (1996).
102. Bathum, L., Andersen-Ranberg, K., Boldsen, J., Brosen, K. and Jeune, B.: Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevity. Eur. J. Clin. Pharmacol., 54: 427-430 (1998).
103. Ruas, J. L. and Lechner, M. C.: Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics, 7: 333-335 (1997).
104. Hoskins, J. M., Shenfield, G. M. and Gross, A. S.: Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br. J. Clin. Pharmacol., 46: 499-504 (1998).
105. Aynacioglu, A. S., Sachse, C., Bozkurt, A., Kortunay, S., Nacak, M., Schroder, T., Kayaalp, S. O., Roots, I. and Brockmoller, J.: Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther., 66: 185-192 (1999).
106. Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L.L. and Ingelman-Sundberg, M.: Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics, 11: 417-427 (2001).
107. Dandara, C., Masimirembwa, C. M., Magimba, A., Sayi, J., Kaaya, S., Sommers, D. K., Snyman, J. R. and Hasler, J. A.: Genetic polymorphism of CYP2D6 and CYP2C19 in East-and Southern African populations including psychiatric patients. Eur. J. Clin. Pharmacol., 57: 11-17 (2001).
108. Bradford, L. D., Gaedigk, A. and Leeder, J. S.: High frequency of CYP2D6 poor and “intermediate” metabolizers in black populations: a review and preliminary data. Psychopharmacol. Bull., 34: 797-804 (1998).
109. Forbes, N. S., Bradford, L. D., Gotschall, R. R., Leeder, J. S. and Gaedigk, A.: CYP2D6 allele frequencies in African Americans: phenotype concordance with dextromethorphan. Clin. Pharmacol. Ther., 65: 170 (1999).
110. Griese, E. U., Asante-Poku, S., Ofori-Adjei, D., Mikus, G. and Eichelbaum, M.: Analysis of the CYP2D6 gene mutation and their consequences for enzyme function in a West African population. Pharmacogenetics, 9: 715-723 (1999).
111. Masimirembwa, C., Hasler, J., Bertilssons, L., Johansson, I., Ekberg, O. and Ingelman-Sundberg, M.: Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2Din a black zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur. J. Clin. Pharmacol., 51: 117-122 (1996).
112. Akillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F. and Ingelman-Sundberg, M.: Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther., 278: 441-446 (1996).
113. Bathum, L., Skjelbo, E., Matabingwa, T. K., Madsen, H., Horder, M. and Brosen, K.: Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br. J. Clin. Pharmacol., 48: 395-401 (1999).
114. Masimirembwa, C., Persson, I., Bertilsson, L., Hasler, J. and Ingelman-Sundberg, M.: A novel mutant variant of the CYP2D6 gene (CYP2D6*common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol., 42: 713-719 (1996).
115. Persson, I., Aklillu, E., Rodrigues, F., Bertilsson, L. and Ingelman-Sundberg, M.: S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics, 6: 521-526 (1996).
116. Herrlin, K., Massele, A. Y., Jande, M., Alm, C., Tybring, G., Abdi, Y. A., Wennerholm, A., Johansson, I., Dahl, M.-L., Bertilsson, L. and Gustafsson, L. L.: Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther., 64: 391-401 (1998).
117. Masimirembwa, C., Bertilsson, L., Johansson, I., Hasler, J. A. and Ingelman-sundberg, M.: Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2Cin a Shona population of Zimbabwe. Clin. Pharmacol. Ther., 57: 656-661 (1995).
118. Edeki, T. I., Goldstein, J. A., de Morais, S. M. F., Hajiloo, L., Butler, M., Chapdelaine, P. and Wilkinson, G. R.: Genetic polymorphism of S-mephenytoin 4?-hydroxylation in African-Americans. Pharmacogenetics, 6: 357-360 (1996).
119. McLellan, R. A., Oscarson, M., Seidegard, J., Evans, D. A. and Ingelman-Sundberg, M.: Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics, 7: 187-191 (1997).
120. Kortunay, S., Bozkurt, A., Bathum, L., Basci, N. E., Calguneri, M., Brosen, K. and Kayaalp,S. O.: CYP2D6 polymorphism in systemic lupus erythematosus patients. Eur. J. Clin. Pharmacol., 55: 21-25 (1999).
121. Hadidi, H. F., Cholerton, S., Monkman, S. C., Armstrong, M., Irshåid, Y. M., Rawashdeh, N. M., Daly, A. K. and Idle, J. R.: Debrisoquine 4-hydroxylation (CYP2Dpolymorphism in Jordanians. Pharmacogenetics, 4: 159-161 (1994).
122. Kortunay, S., Bozkurt, A., Bathum, L., Basci, N. E., Calgüneri, M., Brosen, K. and Kayaap, S. O.: CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Ann. Rheum. Dis., 58: 182-185 (1999).
123. Sviri, S., Shpizen, S., Leitersdorf, E., Levy, M. and Caraco, Y.: Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin. Pharmacol. Ther., 65: 275-282 (1999).
124. Kalow, W., Otton, S. V., Kadar, D., Endrenyi, L. and Inaba, T.: Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can. J. Physiol. Pharmacol., 58: 1142-1144 (1980).
125. Xu, X.-M. and Jiang, W.-D.: Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population. Acta. Pharmacol. Sinica., 11: 385-388 (1990).
126. Holland, P., Barry, M. and Feely, J.: Pharmacogenetics and drug metabolism: An Irish perspective. Ir. J. Med. Sci., 160: 54-56 (1991).
127. Inaba, T., Otton, S. V., Sc, M. and Kalow, W.: Debrisoquine hydroxylation capacity: Problems of assessment in two populations. Clin. Pharmacol. Ther., 29: 218-223 (1981).
128. Wanwimolruk, S., Patamasucon, P. and Lee, E. J. D.: Evidence for the polymorphic oxidation of debrisoquine in the Thai population. Br. J. Clin. Pharmacol., 29: 244-247 (1990).
129. Lee, E. J. D., Nam, Y. P. and Hee, G. N.: Oxidation phenotyping in Chinese and Malay populations. Clin. Exp. Pharmacol. Psysiol., 15: 889-891 (1988).
130. Ismail, R., Hussein, A., The, L. K. and Isa, M. N.: CYP2D6 phenotypes among Malays in Malaysia. J. Clin. Pharm. Ther., 25: 379-383 (2000).
131. Johansson, I., Yue, Q. Y., Dahl, M.-L., Heim, M., Säwe, J., Bertilsson, L., Meyer, U. A., Sjæqvist, F. and Ingelman-Sundberg, M.: Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur. J. Clin. Pharmacol., 40: 553-556 (1991).
132. Wanwimolruk, S., Thou, M. R. and Woods, D. J.: Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Br. J. Clin. Pharmacol., 40: 166-169 (1995).
133. Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, M. D., Wilkinson, G. R. and Branch, R. A.: Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther., 38: 402-408 (1985).
134. Chiba, M., Yokoi, T., Nemoto, N., Inaba, M., Kinoshita, M. and Kamataki, T.: A new variant CYP2D6 allele (CYP2D6*with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics, 9: 287-293 (1999).
135. Bertilsson, L., Lou, Y.-Q., Du, Y.-L., Liu, Y., Kuang, T.-Y., Liao, X.-M., Wang, K.-Y., Reviriego, J., Iselius, L. and Sjoqvist, F.: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther., 51: 388-397 (1992).
136. Brosen, K., Skjelbo, E. and Flachs, H: Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br. J. Clin. Pharmacol., 36: 105-108 (1993).
137. Ishizaki, T., Eichelbaum, M., Horai, Y., Hashimoto, K., Chiba, K. and Dengler, H. J.: Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br. J. Clin. Pharmacol., 23: 482-485 (1987).
138. Abraham, B. K., Adithan, C., Shashindran, C. H. and Vasu, S.: Genetic polymorphism of CYP2D6 in a Kera-lite (South India) population. Br. J. Clin. Pharmacol., 49: 285-288 (2000).
139. Mamidi, R.N.V.S., Satyavaheeswaran, S., Vakkalanka, S. V. S., Chaluvadi, M. R., Katneni, K., Brahmadevara, N., Damodarram, G. and Subramaniam, S.: Polymorphism of dextromethorphan oxidation in South Indian subjects. Clin. Pharmacol. Ther., 66: 193-200 (1999).
140. Nagai, N., Kawakubo, T., Kaneko, F., Ishii, M., Shinohara, R., Saito, Y., Shimamura, H., Ohnishi, A. and Ogata, H.: Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population. Biopharm. Drug Dispos., 17: 421-433 (1996).
141. Nowak, M. P., Tyndale, R. F. and Sellers, E. M.: CYP2D6 phenotype and genotype in a Canadian native Indian population. Pharmacogenetics, 7: 145-148 (1997).
142. Cai, W.-M., Chen, B., Liu, Y.-X. and Chu, X.: Dextromethorphan metabolic phenotyping in a Chinese population. Acta Pharmacol. Sin., 18: 441-444 (1997).
143. Straka, R. J., Hansen, S. R., and Walker, P. F.: Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 hmong subjects and 280 white subjects residing in Minnesota. Clin. Pharmacol. Ther., 58: 29-34 (1995).
144. Evans, D. A., Krahn, P. and Narayanan, N.: The mephenytoin (cytochrome P450 2Cand dextromethorphan (cytochrome P450 2Dpolymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics, 5: 64-71 (1995).
145. Abraham, B. K., Adithan, C., Kiran, P.U., Mohammed, A.S.A.D. and Koumaravelou, K.: Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India. Acta. Pharmacol. Sin., 21: 494-498 (2000).
146. Lamba, V., Lamba, J. K., Dilawari, J. B. and Kohli, K. K.: Genetic polymorphism of CYP2D6 in North Indian subjects. Eur. J. Clin. Pharmacol., 54: 787-791 (1998).
147. Setiabudy, R., Kusaka, M., Chiba, K., Darmansjah, I. and Ishizaki, T.: Dapsone N-acetylation, metoprolol a-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: A cocktail and extended phenotyping assessment trial. Clin. Pharmacol. Ther., 56: 142-153 (1994).
148. Yoon, Y.-R., Cha, I.-J., Shon, J.-H., Kim, K.-A., Cha, Y.-N., Jang, I.-J., Park, C.-W., Shin, S.-G., Folckhart, D. A. and Shin, J.-G.: Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin. Pharmacol. Ther., 67: 567-576 (2000).
149. Tu, Z.-G. and Zhao, L.-L.: Metoprolol a-hydroxylation capacity in 96 Chinese Han volunteers. Chung Kuo Yao Li Hsueh Pao, 16: 325-329 (1995).
150. Horai, Y., Nakano, M., Ishizaki, T., Ishikawa, K., Zhou, H.-H., Zhou, B.-J., Liao, C.-L. and Zhang, L.-M.: Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther., 46: 198-207 (1989).
151. Zhang, Y.-Y. and Jiang, W.-D.: Study on metoprolol metabolism in a Chinese population of healthy volunteers. Chin. J. Clin. Pharmacol., 6: 158-164 (1990).
152. Sohn, D.-R., Shin, S.-G., Park, C.-W., Kusaka, M., Chiba, K. and Ishizaki, T.: Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br. J. Clin. Pharmacol., 32: 504-507 (1991).
153. Jurima, M., Inaba, T., Kadar, D. and Kalow, W.: Genetic polymorphism of mephenytoin p(4?)-hydroxylation: difference between Orientals and Caucasians. Br. J. Clin. Pharmacol., 19: 483-487 (1985).
154. Ruan, Z.-R., Cheng, Y.-S., Zhou, J.-F., Zhao, Y., Pan, Y.-Z. and Ding, D.-Y.: Genetic polymorphism of 4?-hydroxylation of S-mephenytoin in 148 Chinese of Han nationality. Acta Pharmacol. Sin., 17: 119-121 (1996).
155. Xie, H.-G., Huang, S.-L., Xu, Z.-H., Xiao, Z.-S., He, N. and Zhou, H.-H.: Evidence for the effect of gender on activity of (S)-mephenytoin 4?-hydroxylase (CYP2Cin a Chinese population. Pharmacogenetics, 7: 115-119 (1997).
156. Sohn, D.-R., Kusaka, M., Ishizaki, T., Shin, S.-G., Jang, I.-J., Shin, J.-G. and Chiba, K.: Incidence of S-mephenytoin hydroxylation deficiency in Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin. Pharmacol. Ther., 52: 160-169 (1992).
157. Sarich, T., Kalhorn, T., Magee, S., Al-Sayegh, F., Adams, S., Slattery, J., Goldsstein, J., Nelson, S. and Wright, J.: The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin. Pharmacol. Ther., 62: 21-28 (1997).
158. Doshi, B. S., Kulkarni, R. D. and Chauhan, B. L.: Frequency of impaired mephenytoin 4?-hydroxylation in an Indian population. Br. J. Clin. Pharmacol., 30: 779-780 (1990).
159. Daly, A. K., Armstrong, M., Monkman, S. C., Idle, M. E. and Idle, J. R.: Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502Dphenotypes. Pharmacogenetics, 1: 33-41 (1991).
160. Vincent-Viry, M., Muller, J., Fournier, B., Galteau, M. M. and Siest, G.: Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population. Clin. Chem., 37: 327-332 (1991).
161. Leclercq, V., Desager, J. P., van Nieuwenhuyze, Y. and Harvengt, C.: Prevalence of drug hydroxylator phenotypes in Belgium. Eur. J. Clin. Pharmacol., 33: 439-440 (1987).
162. Kunicki, P. K., Sitkiewicz, D., Pawlik, A., Bielicka-Sulzyc, V., Borowiecka, E., Gawrońska-Szklarz, B., Sterna, R., Matsumoto, H. and Radziwon-Zaleska, M.: Debrisoquine hydroxylation in a Polish population. Eur. J. Clin. Pharmacol., 47: 503-505 (1995).
163. Béla, G., Kálmán, R., ádám, V. and Antal, E. K.: A debrisoquine hydroxilacio polimorfizmusanak vizsgala-ta. Orv. Hetil., 127: 2299-2301 (1986).
164. Barbeau, A., Cloutier, T., Roy, M., Plasse, L., Paris, S. and Poirier, J.: Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 30: 1213-1215 (1985).
165. Peart, G. F., Boutagy, J. and Shenfield, G. M.: Debrisoquine oxidation in an Australian population. Br. J. Clin. Pharmacol., 21: 465-471 (1986).
166. Wanwimolruk, S., Denton, J. R., Ferry, D. G. and Beasley, M.: Polymorphism of debrisoquine oxidation in New Zealand Caucasians. Eur. J. Clin. Pharmacol., 42: 349-350 (1992).
167. Duché, J.-C., Joanne, C., Barré, J., de Cremoux, H., Ddalphine, J. C., Depierre, A., Brochard, P., Tillement, J. P. and Bechtel, P.: Lack of relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br. J. Clin. Pharmacol., 31: 533-536 (1991).
168. Arvela, P., Kirjarinta, M., Kirjarinta, M., Karki, N. and Pelkonen, O.: Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br. J. Clin. Pharmacol., 26: 601-603 (1988).
169. Kallio, J., Lindberg, R., Huupponen, R. and Iisalo, E.: Debrisoquine oxidation in a Finnish population: the effect of oral contraceptive on the metabolic ratio. Br. J. Clin. Pharmacol., 26: 791-795 (1988).
170. Evans, D. A. P., Mahgoub, A., Sloan, T. P. and Idle, J. R.: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet., 17: 102-105 (1980).
171. Steiger, M. J., Lledo, P., Quinn, N. P., Marsden, C. D., Turner, P. and Jenner, P. G.: Debrisoquine hydroxylation in Parkinson's disease. Acta. Neurol. Scand., 86: 159-164 (1992).
172. Steventon, G. B., Heafield, M. T. E., Sturman, S. G., Waring, R. H., Williams, A. C. and Ellingham, J.: Degenerative neurological disease and debrisoquine-4-hydroxylation capacity. Med. Sci. Res., 17: 163-164 (1989).
173. Philip, P. A., Rogers, H. J. and Harper, P. G.: Acetylation and oxidation phenotypes in malignant lymphoma. Cancer Chemother. Pharmacol., 20: 235-238 (1987).
174. Sanz, E. J., Villen, T., Alm, C., and Bertilsson, L.: S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin. Pharmacol. Ther., 45: 495-499 (1989).
175. Saner, H., Gurtner, H. P., Preisig, R. and Kupfer, A.: Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate. Eur. J. Clin. Pharmacol., 31: 437-442 (1986).
176. Benitez, J., Barquero, M. S., Coria, F., Molina, J. A., Jiménez-Jiménez, F. J. and Ladero, J. M.: Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimer's disease. J. Neurol. Sci., 117: 8-11 (1993).
177. Siegmund, W., Fengler, J. D., Franke, G., Zschiesche, M., Eike, O., Eike, E., Meisel, P. and Wulkkow, R.: N-Acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Br. J. Clin. Pharmacol., 32: 467-472 (1991).
178. Siegmund, W., Hanke, W., Zschiesche, M., Franke, G., Biebler, K. E. and Wilke, A.: N-acetylation and debrisoquine type oxidation polymorphism in Caucasians-with reference to age and sex. Int. J. Clin. Pharmacol. Ther. Toxicol., 28: 504-509 (1990).
179. Bock, K. W., Schrenk, D., Forster, A., Griese, E.-U., Morike, K., Brockmeier, D. and Eichelbaum, M.: The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics, 4: 209-218 (1994).
180. Evans, D. A. P., Harmer, D., Downham, D. Y., Whibley, E. J., Idle, J. R., Ritchie, J. and Smith, R. L.: The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J. Med. Genet., 20: 321-329 (1983).
181. Eichelbaum, M., Reetz, K. P., Schmidt, E. K. and Zekorn, C.: The genetic polymorphism of sparteine metabolism. Xenobiotica, 16: 465-481 (1986).
182. Breimer, D. D., Danhof, M. and Schellens, J. H. M.: Poor metabolizer incidence of sparteine, mephenytoin and nifedipine in a dutch population as assessed by a “Cocktail” approach. Br. J. Pharmacol., 89: 478 (1986).
183. Orzechowska-Juzwenko, K., Pawlik, J., Niewiński, P., Milejski, P., Dembowski, J., Turek, J., Goździk, A., Swiebodzki, L. and Hora, Z.: Genetically determined sparteine oxidation polymorphism in a Polish population. Eur. J. Clin. Pharmacol., 46: 481-483 (1994).
184. Vink, A., Tnaba, T., Otton, S. V. and Kalow, W.: Sparteine metabolism in Canadian Caucasians. Clin. Pharmacol. Ther., 31: 23-29 (1982).
185. Caporaso, N. E., Lerman, C., Audrain, J., Boyd, N. R., Main, D., Issaq, H. J., Utermahlan, B., Falk, R. T. and Shields, P.: Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol. Biomarkers Prev., 10: 261-263 (2001).
186. Duché, J.-C., Querol-Ferrer, V., Barré, J., Mesangeau, M. and Tillement, J.-P.: Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Int. J. Clin. Pharmacol. Ther. Toxicol., 31: 392-398 (1993).
187. Tamminga, W. J., Wemer, J., Oosterhuis, B., Wieling, J., Wilffert, B., de Leij, L.F.M.H., de Zeeuw, R. A. and Jonkman, J. H. G.: CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur. J. Clin. Pharmacol., 55: 177-184 (1999).
188. Vetticaden, S. J., Cabana, B. E., Prasad, V. K., Purich, E. D., Jonkman, J. H. J., de Zeeuw, R., Ball, L., Leeson, L. J. and Braun, R. L.: Phenotypic differences in dextromethorphan metabolism. Pharm. Res., 6: 13-19 (1989).
189. Spina, E., Campo, G. M., Avenoso, A., Caputi, A. P. Zuccaro, P., Pacifici, R., Gatti, G., Strada, G., Bartoli, A. and Perucca, E.: CYP2D6-related oxidation polymorphism in Italy. Pharm. Res., 29: 281-289 (1994).
190. Kiivet, R. A., Svensson, J.-O., Bertilsson, L. and Sjoqvist, F.: Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. Pharmacol. Toxicol., 72: 113-115 (1993).
191. Britzi, M., Bialer, M., Arcavi, L., Shachbari, A., Kapitulnik, T. and Soback, S.: Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Ther. Drug Monit., 22: 510-516 (2000).
192. Schmid, B., Bircher, J., Preisig, R. and Kupfer, A.: Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther., 38: 618-624 (1985).
193. Hildebrand, M., Seifert, W. and Richenberger, A.: Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur. J. Clin. Pharmacol., 36: 315-318 (1989).
194. Jacqz, E., Dulac, H. and Mathieu, H.: Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur. J. Clin. Pharmacol., 35: 167-171 (1988).
195. Vincent-Viry, M., Fournier, B., Siest, G. and Galteau, M. M.: Dextromethorphan O-demethylation in a large number of French Caucasian families. Pharmacogenetics, 2: 135-138 (1992).
196. Larrey, D., Amouyal, G., Tinel, M., Letteron, P., Berson, A., Labbe, G. and Pessayre, D.: Polymorphism of dextromethorphan oxidation in a French population. Br. J. Clin. Pharmacol., 24: 676-679 (1987).
197. Jacqz-Aigrain, E., Frunk-Brentano, C. and Cresteil, T.: CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3: 197-204 (1993).
198. Brockmoller, J., Rost, K. L., Gross, D., Schenkel, A. and Roots, I.: Phenotyping of CYP2C19 with enan-tiospecific HPLC-quatification of R-and S-mephenytoin and comparison with the intron4/exon5 G to A-splice site mutation. Pharmacogenetics, 5: 80-88 (1995).
199. Reviriego, J., Bertilsson, L., Carrillo, J. A., Llerena, A., Valdivielso, M. J. and Benitez, J.: Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. Eur. J. Clin. Pharmacol., 44: 593-595 (1993).
200. Balian, J. D., Sukhova, N., Harris, J. W., Hewett, J., Pickle, R. N. L., Goldstein, J. A., Woosley, R. L. and Flockhart, D. A.: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin. Pharmacol. Ther., 57: 662-669 (1995).
201. Mbanefo, C., Bababunmi, E. A., Mahgoub, A., Sloan, T. P., Idle, J. R. and Smith, R. L.: A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica, 10: 811-888 (1980).
202. Lennard, M. S., Iyun, A. O., Jackson, P. R., Tucker, G. T. and Woods, H. F.: Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics, 2: 89-92 (1992).
203. Sommers, D. K., Moncrieff, J. and Avenant, J. C.: Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of South Africa. Hum. Toxicol., 7: 273-276 (1988).
204. Mahgoub, A., Idle, J. R. and Smith, R. L.: A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica, 9: 51-56 (1979).
205. Sommers, D. K., Moncrieff, J. and Avenant, J. C.: Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum. Toxicol., 8: 365-368 (1989).
206. Wennerholm, A., Johansson, I., Massele, A. Y., Jande, M., Alm, C., Aden-Abdi, Y., Dahl, M.-L., Ingelman-Sundberg, M., Bertilsson, L. and Gustafsson, L. L.: Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics, 9: 707-714 (1999).
207. Simooya, O. O., Njunju, E., Hodjegan, A. R., Lennard, M. S. and Tucker, G. T.: Debrisoquine and metoprolol oxidation in Zambians; a population study.Pharmacogenetics, 3: 205-208 (1993).
208. Sommers, D. K., Moncrieff, J. and Avenant, J.: Polymorphism in sparteine oxidation in the Barakwena (Kwengo) of Southern Africa. South African J. Sci., 86: 28-29 (1990).
209. Ritchie, J. C., Mitchell, S. C. and Smith, R. L.: Sparteine metabolism in a Nigerian population. Drug Metabol. Drug Interact., 13: 129-135 (1996).
210. Sommers, D. K., Moncrieff, J. and Avenant, J. C.: Absence of polymorphism of sparteine oxidation in the South African Venda. Hum. Exp. Toxicol., 10: 175-178 (1991).
211. Nsabiyumva, F., Furet, Y., Autret, E., Jonville, A. P. and Breteau, M.: Oxidative polymorphism of dextromethorphan in a Burundi population. Eur. J. Clin. Pharmacol., 41: 75-77 (1991).
212. Panserat, S., Sica, L., Gerard, N., Jacqz-Aigrain, E. and Krishnamoorthy, R.: CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br. J. Clin. Pharmacol., 47: 121-124 (1999).
213. Marinac, J. S., Foxworth, J. W. and Willsie, S. K.: Dextromethorphan polymorphic hepatic oxidation (CYP2Din healthy black American adult subjects. Ther. Drug Monit., 17: 120-124 (1995).
214. Sommers, D. K., Moncrieff, J. and Avenant, J. C.: Metoprolol a-hydroxylation polymorphism in the San Bushmen of Southern Africa. Hum. Toxicol., 8: 39-43 (1989).
215. Skjelbo, E., Mutabingwa, T. K., Bygbjerg, I., Nielsen, K. K., Gram, L. F. and Brosen, K.: Chloroguanide metabolism in relation to the effiency in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin. Pharmacol. Ther., 59: 304-311 (1996).
216. Iyun, A. O., Tucker, G. T., Woods, H. F. and Lennard, M. S.: The 4-hydroxylation of (S)-mephenytoin in Nigerians: a population study. [(Abstract)]. Br. J. Clin. Pharmacol., 30: 312 P (1990).
217. Attitallah, S., Berard, M., Belkahia, C., Bechtel, Y.C. and Bechtel, P.R.: Similarities and/or dissimilarities of CYP2D6 polymorphism in three Tunisian ethnic groups: Arabs, Berbers, Numides. Therapie, 55: 355-360 (2000).
218. Islam, S. I., Idle, J. R. and Smith, R. L.: The polymorphic 4-hydroxylation of debrisoquine in a Saudi Arab population. Xenobiotica, 10: 819-825 (1980).
219. Sardas, S. Pontin, J. and Idle, J. R.: Polymorphic 4-hydroxylation of debrisoquine in a Turkish population. Pharmacogenetics, 1: 123-124 (1991).
220. Bozkurt, A., Basci, N. E., Isimer, A., Sayal, A. and Kayaalp, S. O.: Polymorphic debrisoquin metabolism in a Turkish population. Clin. Pharmacol. Ther., 55: 399-401 (1994).
221. Irshaid, Y. M., Al-Hadidi, H. F. and Rawashdeh, N. M.: Dextromethorphan O-demethylation polymorphism in Jordanians. Eur. J. Clin. Pharmacol., 45: 271-273 (1993).
222. Al-Hadidi, H. F., Irshaid, Y. M. and Rawashdeh, N. M.: Metoprolol a-hydroxylation is a poor probe for debrisoquine oxidation (CYP2Dpolymorphism in Jordanians. Eur. J. Clin. Pharmacol., 47: 311-314 (1994).
223. Hadidi, H. F., Irshaid, Y. M., Woosey, R. L., Idle, J. R. and Flockhart, D. A.: S-mephenytoin hydroxylation phenotypes in a Jordanian population. Clin. Pharmacol. Ther., 58: 542-547 (1995).
224. Yokoi, T. and Kamataki, T.: Genetic polymorphism of drug metabolizing enzymes: New mutations in CYP2D6 and CYP2A6 genes in Japanese. Folia Pharmacol. Jpn., 112: 5-14 (1998).